Abstract
The treatment of disseminated melanoma is inadequate. The most active single agents provide brief objective response in 20% of patients, while the combination chemotherapy improves response rates without any apparent survival benefit. Median overall survival is, in fact, 7-9 months and 5 year survival is approximately 6%. Metastatic melanoma with a localization of the disease in the liver and brain are categorized as M1c and have the worst prognosis. Here we describe the history, treatment and favourable clinical outcome in a young man with liver and resected brain metastases who obtained complete remission for 6 years since chemotherapy with dacarbazine, cisplatin and vinblastine.
Original language | English |
---|---|
Pages (from-to) | 1429-1431 |
Number of pages | 3 |
Journal | Anticancer Research |
Volume | 28 |
Issue number | 2 B |
Publication status | Published - Mar 2008 |
Keywords
- Long-term survival
- Melanoma
- Metastatic disease
ASJC Scopus subject areas
- Cancer Research
- Oncology